Morgan Stanley Ranks EU Diagnostics Stocks by China Reform Risk

By EC Assets · Published 25 August 2026

Morgan Stanley has assessed the exposure of European Union diagnostics stocks to reforms in China. The firm ranked these companies based on the potential impact of changes in Chinese policy. Separately, Morgan Stanley upgraded Quest Diagnostics to Overweight from Equal Weight on December 17, 2024. The firm raised its price target for Quest Diagnostics to $172 from $145. Morgan Stanley indicated it sees "incremental clarity" regarding Quest's medium and longer term outlook. Quest Diagnostics' Executive Vice President and Chief Financial Officer, Sam Samad, is scheduled to speak at the Morgan Stanley 24th Annual Global Healthcare Conference. This article is intended for informational purposes only. It does not constitute investment advice.